From the Journals

COVID-19 antibody response not reduced with diabetes

Publish date: October 20, 2020

 

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
MDedge Emergency Medicine
Exercise cuts diabetes death risk by a third in two studies
MDedge Emergency Medicine
Higher glycemic time in range may benefit T2D patients
MDedge Emergency Medicine
Geriatric patients: My three rules for them
MDedge Emergency Medicine
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
MDedge Emergency Medicine
Dapagliflozin’s CKD performance sends heart failure messages
MDedge Emergency Medicine
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
MDedge Emergency Medicine
Empagliflozin cut PA pressures in heart failure patients
MDedge Emergency Medicine
T2D treatments create tension between glycemic and cardiovascular goals
MDedge Emergency Medicine
Recall widens for diabetes drug metformin
MDedge Emergency Medicine